https://www.selleckchem.com/pr....oducts/mito-tempo.ht
edominant reperfusion strategy, supporting current recommendations. Intensive systolic blood pressure (SBP) treatment prevents cardiovascular disease (CVD) events in patients with high CVD risk on average, though benefits likely vary among patients. The aim of this study was to predict the magnitude of benefit (reduced CVD and all-cause mortality risk) along with adverse event (AE) risk from intensive versus standard SBP treatment. This was a secondary analysis of SPRINT (Systolic Blood Pressure Intervention Trial). Separate benefit
Like
Comment
Share
